Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary ciliary dyskinesia (PCD), also known as Kartagener syndrome, is a genetic disorder of the cilia, which are microscopic hair-like cells. Cilia work to keep the respiratory system clean by moving mucus that contains debris to the large airways, where it can be coughed out. People with PCD have cilia that do not move properly and therefore are not effective in cleaning the respiratory system. This study will determine when PCD starts and how it changes over time, specifically in terms of how well the lungs work, what germs grow in lung secretions, and how the lungs look on computed tomography (CT) scans.
| Condition |
|---|
|
Kartagener Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Early Onset and Progression of Primary Ciliary Dyskinesia Lung Disease Prior to 10 Years of Age |
- Infant lung function [ Time Frame: Measured at initial study visit (for children under 3) ] [ Designated as safety issue: No ]
- Spirometry measures [ Time Frame: Measured yearly for 5 years (after age of 3 years) ] [ Designated as safety issue: No ]
- Respiratory cultures [ Time Frame: Measured yearly for 5 years ] [ Designated as safety issue: No ]
- Chest CT scan results [ Time Frame: Measured at the initial study visit and at Years 3 and 5 ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Approximately 2 teaspoons of blood and a small amount of urine (if the child is able to urinate in a cup) will be collected and held at the specimen bank located at Denver Children's Hospital. These samples will be used to help identify markers that may predict the clinical course of PCD.
| Estimated Enrollment: | 48 |
| Study Start Date: | July 2008 |
| Estimated Study Completion Date: | July 2015 |
| Estimated Primary Completion Date: | July 2015 (Final data collection date for primary outcome measure) |
PCD, or Kartagener syndrome, is a genetic disorder that causes hair-like cells called cilia to move improperly, or in some cases, not at all. Cilia are needed to help clear the respiratory system of pollutants. When they work properly, they move debris-filled mucus into the large airways, allowing the debris to be coughed out of the body. When the cilia do not work properly, the body cannot rid itself of debris and is left vulnerable to serious infections in the sinuses, ears, and lungs. Over time, repeated infections can lead to scarring and permanent obstruction of these body areas. This study will determine when PCD starts and how it changes over time, specifically in terms of how well the lungs work, what germs grow in lung secretions, and how the lungs look on CT scans. This research may lead to a better understanding of PCD and thereby help doctors improve clinical management of the disease.
Children in this study will attend six study visits over 5 years. At the first visit, parents will review their child's medical and cough history with doctors. Also at this visit, children will undergo a physical exam that will include measures of temperature, blood pressure, heart rate, respiration rate, and oxygen saturation level. Additional procedures will include collection of a respiratory mucus sample or a throat culture, measurement of nasal nitric oxide, collection of blood and urine for specimen banking, a CT scan, and lung function testing. Children younger than 3 years of age will undergo the scan and lung function test under sedation. Children older than 3 years of age will not receive sedation. CT scans will be performed at the initial visit and during the visits 3 and 5 for children older than 3. For children younger than 3 years, chest CT scans will be performed at the initial visit and during visits 4 and 6. Lung function tests and blood and urine collection may be repeated at some of the remaining yearly visits. Between yearly visits, parents will track on a calendar their children's use of oral, inhaled, and intravenous antibiotics.
Eligibility| Ages Eligible for Study: | up to 4 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Participants in this study will be children younger than 5 years of age who have been diagnosed with PCD as based on electron microscopy and/or presence of two known disease-causing gene mutations or for whom a diagnosis of PCD has been determined probable as based on clinical features and very low nasal nitric oxide (less than 60 nl/minute).
Inclusion Criteria:
- Younger than 5 years of age
- Diagnosis of PCD or probable PCD based on criteria listed above
- Parent or legal guardian willing to give informed consent
Exclusion Criteria:
- Unable to attend follow-up appointments
- History of lung transplant
- Any co-existing severe diseases that may have significant impact on lung function, respiratory infections, or overall health status (i.e., severe congenital heart disease, severe scoliosis, AIDS, cancer, or end-stage kidney disease)
Contacts and Locations| United States, California | |
| Stanford University, Palo Alto | |
| Palo Alto, California, United States, 94304 | |
| United States, Colorado | |
| The Children's Hospital, Denver | |
| Denver, Colorado, United States, 80045 | |
| United States, Missouri | |
| Washington University in St. Louis | |
| St. Louis, Missouri, United States, 63110 | |
| United States, North Carolina | |
| University of North Carolina, Chapel Hill | |
| Chapel Hill, North Carolina, United States, 27599 | |
| United States, Washington | |
| Children's Hospital and Regional Medical Center, Seattle | |
| Seattle, Washington, United States, 98105 | |
| Canada, Ontario | |
| The Hospital for Sick Children, Toronto | |
| Toronto, Ontario, Canada, M5G 1X8 | |
| Study Chair: | Margaret W. Leigh, MD | University of North Carolina, Chapel Hill |
| Study Chair: | Margaret Rosenfeld, MD, MPH | Seattle Children's Hospital |
More Information
Additional Information:
Publications:
| Responsible Party: | Margaret Leigh, MD, Professor of Pediatrics, University of North Carolina, Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT00722878 History of Changes |
| Other Study ID Numbers: | RDCRN 5903, 9-U54-HL096458 |
| Study First Received: | July 24, 2008 |
| Last Updated: | October 24, 2012 |
| Health Authority: | United States: Federal Government United States: Institutional Review Board |
Keywords provided by University of North Carolina, Chapel Hill:
|
Primary Ciliary Dyskinesia |
Additional relevant MeSH terms:
|
Ciliary Motility Disorders Kartagener Syndrome Dyskinesias Lung Diseases Disease Progression Respiratory Tract Diseases Otorhinolaryngologic Diseases Bronchiectasis Bronchial Diseases Respiratory System Abnormalities Dextrocardia Heart Defects, Congenital Cardiovascular Abnormalities |
Cardiovascular Diseases Heart Diseases Congenital Abnormalities Situs Inversus Genetic Diseases, Inborn Movement Disorders Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms Disease Attributes Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013